Infliximab in the treatment of patients with Crohn's disease: preliminary report

Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation. To assess th...

Full description

Saved in:
Bibliographic Details
Published in:Revista medíca de Chile 2006-03, Vol.134 (3), p.320-325
Main Authors: Gellona V, José, Zarraonandia A, Antón, Zúñiga D, Alvaro, Palma C, Renato, Contreras P, Jaime, Silva Ch, Jaime, González D, Róbinson, Quintana V, Carlos
Format: Article
Language:Spanish
Subjects:
Adolescent
Adult
Antibodies, Monoclonal - therapeutic use
Crohn Disease - drug therapy
Female
Gastrointestinal Agents - therapeutic use
Humans
Infliximab
Male
Middle Aged
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation. To assess the effectiveness of Infliximab in patients with Crohn's disease. Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug. CDAI before and after Infliximab administration was 357+/-62 and 138+/-122 score points, respectively (p
ISSN:0034-9887